NEW YORK (GenomeWeb News) – Epigenomics today reported a 67 percent drop year over year in first-quarter revenues.

For the three months ended March 31, the German molecular diagnostics firm reported €200,000 ($258,892) in revenues, down from €600,000 a year ago, when it received a payment from Qiagen for a non-exclusive license to Epigenomics' methylated Septin-9 biomarker.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.